Open an account

Vaxcyte

PCVX · NASDAQ

$66.23+$2.55 (+4.00%)TodayMarket closed ·
Prev close $63.68

About PCVX

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. The company is headquartered in San Carlos, California and currently employs 507 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.

Employees
507
Headquarters
San Carlos, California
Listed
Jun 12, 2020
Sector
Health Care
Industry
Biotechnology
Website
vaxcyte.com

PCVX key statistics

Market cap
10.02B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.66M
Volume
1.96M
Open price
$63.80
High today
$67.01
Low today
$63.68
52 Week high
$90.75
52 Week low
$39.87

Vaxcyte (PCVX) at a glance

Vaxcyte (PCVX) last traded at $66.23, with a market cap of 10.02B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $63.68 and $67.01. The current price is 4.0% above the day's low and 1.2% below its high.

Volume so far is 1.96M shares, below the average of 3.66M shares a day.

Over the past year Vaxcyte has ranged from $39.87 to $90.75, and now sits 52% of the way up that range.

Vaxcyte met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$1.97 per share against an estimate of -$2.10.

The average analyst price target is $110.84, 67.4% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 11 analystsAvg $110.84
Low
$67.67
Now
$66.23
High
$171.15

PCVX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 12.5% on average.

  1. Q3 FY24: reported -$0.83 per share against an estimate of -$1.16
  2. Q4 FY24: reported -$1.01 per share against an estimate of -$1.16
  3. Q1 FY25: reported -$1.04 per share against an estimate of -$1.07
  4. Q2 FY25: reported -$1.22 per share against an estimate of -$1.19
  5. Q3 FY25: reported -$1.56 per share against an estimate of -$1.29
  6. Q4 FY25: reported -$1.80 per share against an estimate of -$1.55
  7. Q1 FY26: reported -$2.30 per share against an estimate of -$1.79
  8. Q2 FY26: reported -$1.97 per share against an estimate of -$2.10

PCVX news

  • Ananya Gairola

    Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'

  • Neeraj Jain

    A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally

  • 'Russia Denies Report of Second Case of Illness in Siberia' - Bloomberg

  • Avi Kapoor

    Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings

  • Rishabh Mishra

    Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Gain as Scott Bessent Doubles Down on Iran Pressure— OPCH, PCVX, STZ in Focus (UPDATED)

  • Mohd Haider

    Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety

  • Avi Kapoor

    Dow Gains 100 Points; ISM Services PMI Falls In September

  • Press releaseGlobe Newswire

    Biotech Brainiacs and Breakthroughs

Similar companies

Companies in the same industry as Vaxcyte

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.